Kamada Ltd (NASDAQ:KMDA) – Equities research analysts at Jefferies Group issued their Q1 2018 earnings per share (EPS) estimates for shares of Kamada in a note issued to investors on Thursday. Jefferies Group analyst R. Denhoy anticipates that the biotechnology company will post earnings per share of $0.02 for the quarter. Jefferies Group also issued estimates for Kamada’s Q2 2018 earnings at $0.06 EPS, FY2018 earnings at $0.23 EPS, FY2019 earnings at $0.42 EPS, FY2020 earnings at $0.62 EPS and FY2021 earnings at $0.38 EPS.

Kamada (NASDAQ:KMDA) last issued its quarterly earnings data on Wednesday, February 7th. The biotechnology company reported $0.16 EPS for the quarter, beating the consensus estimate of $0.06 by $0.10. The firm had revenue of $35.71 million during the quarter, compared to the consensus estimate of $32.90 million. Kamada had a net margin of 6.71% and a return on equity of 9.06%.

Several other brokerages also recently commented on KMDA. Chardan Capital began coverage on shares of Kamada in a research note on Friday, February 2nd. They set a “buy” rating and a $7.00 price objective for the company. ValuEngine downgraded shares of Kamada from a “hold” rating to a “sell” rating in a research note on Friday, February 2nd. HC Wainwright reaffirmed a “buy” rating on shares of Kamada in a research note on Thursday, February 8th. Finally, Zacks Investment Research raised shares of Kamada from a “sell” rating to a “hold” rating in a research note on Wednesday, October 25th. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $7.00.

Kamada (KMDA) opened at $5.00 on Monday. The company has a market cap of $201.31, a PE ratio of 29.41 and a beta of 1.14. The company has a debt-to-equity ratio of 0.02, a quick ratio of 2.58 and a current ratio of 3.30. Kamada has a one year low of $3.75 and a one year high of $8.61.

Large investors have recently modified their holdings of the company. Jane Street Group LLC bought a new position in shares of Kamada during the third quarter valued at about $112,000. Worth Venture Partners LLC bought a new position in shares of Kamada during the third quarter valued at about $246,000. ARK Investment Management LLC bought a new position in shares of Kamada during the fourth quarter valued at about $251,000. Navellier & Associates Inc bought a new position in shares of Kamada during the second quarter valued at about $303,000. Finally, Analyst IMS Investment Management Services Ltd. raised its stake in shares of Kamada by 125.5% during the third quarter. Analyst IMS Investment Management Services Ltd. now owns 89,843 shares of the biotechnology company’s stock valued at $431,000 after acquiring an additional 50,000 shares during the last quarter. 6.26% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: “Kamada Ltd (KMDA) Expected to Post Q1 2018 Earnings of $0.02 Per Share” was first published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this news story on another publication, it was copied illegally and reposted in violation of United States & international copyright and trademark laws. The legal version of this news story can be viewed at https://theolympiareport.com/2018/02/13/kamada-ltd-kmda-expected-to-post-q1-2018-earnings-of-0-02-per-share.html.

Kamada Company Profile

Kamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company’s product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy.

Earnings History and Estimates for Kamada (NASDAQ:KMDA)

Receive News & Ratings for Kamada Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada and related companies with MarketBeat.com's FREE daily email newsletter.